Canaccord Genuity Initiates Coverage On AbbVie with Buy Rating, Announces Price Target of $262

Benzinga Newsdesk www.benzinga.com Positive 52.4%

Neg 0% Neu 0% Pos 52.4%

Canaccord Genuity analyst Gary Nachman initiates coverage on AbbVie (NYSE:ABBV) with a Buy rating and announces Price Target of $262.